BIOGEN INC. - COMMON STOCK

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

25 8 2025 00:00:00 提供 Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

11 8 2025 04:00:00 提供 Nasdaq GlobeNewswire

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

30 7 2025 08:00:00 提供 Nasdaq GlobeNewswire

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

25 7 2025 04:20:26 提供 Nasdaq GlobeNewswire

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

21 7 2025 16:30:00 提供 Nasdaq GlobeNewswire

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

21 7 2025 04:30:00 提供 Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

10 7 2025 04:00:00 提供 Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

30 6 2025 04:30:12 提供 Nasdaq GlobeNewswire

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

27 6 2025 07:00:23 提供 Nasdaq GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

25 6 2025 04:30:37 提供 Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

18 6 2025 04:30:27 提供 Nasdaq GlobeNewswire

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

11 6 2025 22:00:39 提供 Nasdaq GlobeNewswire

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

27 5 2025 04:30:00 提供 Nasdaq GlobeNewswire

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

15 4 2025 16:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

09 4 2025 06:45:15 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 4 2025 10:06:04 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 4 2025 06:45:03 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 4 2025 06:47:36 提供 NetDania Notify

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

02 4 2025 04:30:00 提供 Nasdaq GlobeNewswire

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

24 3 2025 04:30:00 提供 Nasdaq GlobeNewswire